Affiliation: Novartis Institutes for BioMedical Research
- MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety databaseMichele Pellegrini
Global Clinical Research and Development, Novartis Vaccines and Diagnostics, 53100 Siena, Italy
Vaccine 27:6959-65. 2009..Adding adjuvants such as MF59((R)) to influenza vaccines can enhance the immune response. This analysis evaluated the safety profile of MF59-adjuvanted [(+)MF59] compared with non-adjuvanted [(-)MF59] vaccines in a large clinical database...